Cancer immunotherapy

Details Cancer immunotherapy Cancer immunotherapy

2002-03-22

2008-03-04

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07338929

ABSTRACT:
A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2.

REFERENCES:
patent: 5614191 (1997-03-01), Puri et al.
patent: 5710023 (1998-01-01), Collins et al.
patent: 5827703 (1998-10-01), Debs et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 6248714 (2001-06-01), Collins et al.
patent: 2003/0157691 (2003-08-01), Qin et al.
patent: WO 9731946 (1997-09-01), None
patent: WO 01/58479 (2001-08-01), None
patent: WO 02/097114 (2002-12-01), None
patent: WO 03/079757 (2003-10-01), None
Byers, T. (CA Journal, vol. 49, No. 6, Nov./Dec. 1999).
Bellone et al. (Immunology Today, v20 (10), 1999, pp. 457-462).
Gura (Science, v278, 1997, pp. 1041-1042).
Paine-Murrieta et al. (Cancer Chemother.Pharmacol, vol. 40, 1997, pp. 209-214).
Ben-Efraim, Tumor Biology 1999; 20: 1-24.
Marincola et al., TRENDS in Immunology 2003; 24: 334-341.
Frazer, I., Expert. Opin. Pharmacother. 2004; 5: 2427-2434.
Debinski et al., “Human Gliomas Cells Overexpress Receptors for Interleukin 13 and Are Extremely Sensitive to a Novel Chimeric Protein Composed of Interleukin 13 and Pseudomonas Exotoxin1,” Clinical Cancer Research, 1: 1253-1258, 1995.
Debinski et al., “Novel Way To Increase Targeting Specificity to a Numan Glioblastoma-Associated Receptor For Interleukin 13,” Int. J. Cancer, 76: 547-551, 1998.
Caput et al., “Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor α Chain,” The Journal of Biological Chemistry, 271: 16921-16926, 1996.
Debinski, W., “Recombinant Cytotoxins Specific for Cancer Cells,” Ann. NY Acad. Sci., 297-299, 1999.
Debinski et al., “Receptor for Interleukin 13 Is a Marker and Therapeutic Target for Human High-Grade Gliomas1,” Clinical Cancer Research, 5: 985-990, 1999.
Joshi et al., “Interleukin-13 Receptor α Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas,” Cancer Research, 60: 1168-1172, 2000.
Barton et al. “Retroviral delivery of small interfering RNA into primary cells”, PNAS, (2002), vol. 99, No. 23, pp. 14943-14945.
Noda et al. “Protection from Anti-TCR/CD3-Induced Apoptosis in Immature Thymocytes by a Signal Through Thymic Shared Antigen-1/Stem Cell Antigen-2”, J. Exp. Med., (1996), vol. 183, pp. 2355-2360.
Treister et al. “Expression of Ly-6, A Marker for Highly Malignant Murine Tumor Cells, is Regulated by Growth Conditions and Stress”, Int. J. Cancer, (1998), vol. 77, pp. 306-313.
McManus et al. “Gene Silencing in Mammals by Small Interfering RNAs”, Nature Reviews/Genetics, (2002), vol. 3, pp. 737-747.
Tuschl et al. “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy”, Molecular Interventions, (2002), vol. 2, No. 3, pp. 158-167.
Rubinson et al. “A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA Interference”, Nature Genetics, (2003), vol. 33, pp. 401-406.
He et al. “Functional Characterization of Hepatoma-Specific Stem Cell Antigen-2”, Molecular Carcinogenesis, (2004), vol. 40, pp. 90-103.
Banerjea et al. “Inhibition of HIV-1 by Lentiviral Vector-Transduced siRNAs in T Lymphocytes Differentiated in SCID-hu Mice and CD34 Progenitor Cell-Derived Macrophages”, Molecular Therapy, (2003), vol. 8, No. 1, pp. 62-71.
Lee et al. “Inhibition of Human Immunodeficiency Virus Type 1 Replication in Primary Macrophages by Using Tat- or CCR5-Specific Small Interfering RNAs Expressed from a Lentivirus Vector”, Journal of Virology, (2003), vol. 77, No. 22, pp. 11964-11972.
Lee et al. “Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells”, Nature Biotechnology, (2002), vol. 19, pp. 500-505.
Novina et al. “siRNA-directed inhibition of HIV-1 infection”, Nature Medicine, (2002), vol. 8, No. 7, pp. 681-686.
Coburn et al. “Potent and Specific Inhibition of Human Immunodeficiency Virus Type 1 Replication by RNA Interference”, Journal of Virology, (2002), vol. 76, No. 18, pp. 9225-9231.
Boden et al. “Promoter choice affects the potency of HIV-1 specific RNA interference”, Nucleic Acids Research, (2003), vol. 31, No. 17, pp. 5033-5038.
Pusch et al. “Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA”, Nucleic Acids Research, (2003), vol. 31, No. 22, pp. 6444-6449.
Chang et al. “Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1”, Gene Therapy, (2005), vol. 12, pp. 1133-1144.

Affiliated with

Also associated with

Rating

Cancer immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer immunotherapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3965584